Method for enhancing quality of life in patients with diabetes using a cell pouch BIO-hybrid organ
The cell pouch bio-hybrid system addresses mental health issues and glycemic control in diabetes patients by implanting insulin-producing cells, improving emotional well-being and quality of life through enhanced diabetes management.
Patent Information
- Application Number
- PCT/US2026/026948
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Patients with diabetes, particularly those with type 1 diabetes, face significant mental health issues, poor adherence to treatment, and emotional distress due to the burden of diabetes management, which often go undetected and untreated, leading to poor glycemic control and impaired quality of life.
Implantation of a cell pouch bio-hybrid system that supports the vascularization of therapeutic cells, allowing insulin-producing cells to be transplanted and integrated within vascularized tissue chambers, enabling long-term survival and function to manage diabetes through stable glycemic control and emotional health assessments.
The method reduces diabetes-related distress, improves glycemic control, decreases hypoglycemic events, and enhances overall quality of life by increasing awareness and management of hypoglycemia, thereby reducing anxiety and depression symptoms.
Smart Images

Figure US2026026948_12112026_PF_FP_ABST
Abstract
Description
PATENT APPLICATION Attorney Docket No.: 410694-504001WO METHOD FOR ENHANCING QUALITY OF LIFE IN PATIENTS WITH DIABETES USING A CELL POUCH BIO-HYBRID ORGAN AND RELATED METHODSTECHNICAL FIELD
[0001] The embodiments of the present disclosure relate to methods for enhancing quality of life in a patient with diabetes, particularly through the use of a cell pouch bio-hybrid system.BACKGROUND
[0002] Living with diabetes is associated with a broad range of diabetes-related distresses, such as feeling overwhelmed with the diabetes regimen; being concerned about the future and the possibility of serious complications; and feeling guilty when management is going poorly. This disease burden and emotional distress in individuals with diabetes, even at levels of severity below the threshold for a psychiatric diagnosis of depression or anxiety, are associated with poor adherence to treatment, poor glycemic control, higher rates of diabetes complications, and impaired quality of life.
[0003] Indeed, people with type 1 diabetes are at increased risk for various mental health issues, including depression, anxiety, eating disorders, and diabetes distress. Across the lifespan, type 1 diabetes mellitus has a profound (neuro)psychological impact. In young people, type 1 diabetes can interfere with psychosocial development and hamper school performance. In adulthood, it can interfere with work life, relationships and parenting. A substantial minority of adults with type 1 diabetes experience coping difficulties and high diabetes- related distress. In youth and adulthood, type 1 diabetes is related to mild cognitive decrements as well as affective disorders, such as depression and anxiety. Studies show that people with diabetes are 2 to 3 times more likely to experience depression and 20% more likely to experience anxiety. People with type 1 diabetes are twice as likely to live with disordered eating.1'213
[0004] One of the biggest challenges to treatment of mental health conditions for people with diabetes are the low rates of detection. Up to 45 percent of mental health conditions and cases of severe psychological distress go undetected among patients being treated for diabetes. It is estimated that only around 1 / 3 of people with diabetes and mental health conditions receive a diagnosis and proper treatment. This may be because the signs and symptoms that people experience when their blood sugar is too high or too low can be confused for depression or anxiety. People with diabetes also may face stigma in talking about their feelings of depression and tend not to talk about them at appointments. When mental healthAttorney Docket No.: 410694-504001WOcomorbidities of diabetes are not treated, the financial cost to society and health care systems is substantial, as are the morbidity and health consequences for patients.
[0005] Accordingly, there is a need for methods of improving mental health in diabetes patients.BRIEF SUMMARY
[0006] The methods described herein possess several aspects, no single one of which is solely responsible for the desirable therapeutic outcomes. Without limiting the scope of the appended claims, certain features of the disclosure will be briefly discussed. A fuller understanding of how these features provide significant advantages, such as improved glycemic control and reduced diabetes-related distress, will be gained after reading the 'Detailed Description' section that follows.
[0007] The embodiments of the present disclosure provide a method for enhancing the quality of life in patients with diabetes through a cell pouch bio-hybrid system, which may be implanted in the patient to establish a pre-vascularized environment that supports the long-term survival and function of therapeutic cells. Once the system is adequately vascularized, cells expressing insulin may be transplanted into the system. The integration of therapeutic cells within the vascularized tissue chambers of the cell pouch may ensure long-term survival and function, releasing necessary proteins and hormones to treat the disease effectively. These cells can produce and release biologically active molecules, such as insulin, to treat diabetes and achieve insulin independence. The cells expressing insulin can be donor cells, stem cell-derived cells, or xenogeneic cells. The success of the transplantation may be measured in terms of insulin independence, C peptide secretion, or glycemic control, and the engraftment and function of the transplanted cells may be assessed using beta scores. The beta scores may be BETA or BETA-2 scores.
[0008] This approach may offer a solution for managing diabetes, particularly for patients with type 1 diabetes, by integrating advanced cell transplantation techniques with emotional health assessments. The method also involves assessing the patient's emotional health. The emotional health of the patient may be assessed using, e.g., mental health professionals or patient- reported instruments. Some examples of patient-reported instruments include, but are not limited to, the Clarke Hypoglycemia Awareness Scale, the Hypoglycemia Fear Survey-ll, and the Diabetes Distress Score. The system can reduce diabetes-related distress, improve glycemic control, and decrease hypoglycemic events, contributing to an overall enhancement in the patient's life quality.Attorney Docket No.: 410694-504001WQ
[0009] The patient may experience a reduction in the fear of hypoglycemia, which can contribute to an overall improvement in their well-being. The method can lead to an improvement in the patient's awareness of hypoglycemia, enhancing their ability to manage the condition effectively. The patient may experience an increase in sensitivity to hypoglycemic symptoms, allowing for better recognition and management of these symptoms. The method can result in a reduction in anxiety related to diabetes management, providing the patient with a more relaxed approach to handling their condition. The patient may experience a reduction in depression symptoms associated with diabetes, contributing to an improved mental health state.
[0010] Certain aspects of the present disclosure provide a method for enhancing quality of life in a patient with diabetes. The method generally includes implanting a macroencapsulation device in the patient. The method generally includes allowing the implanted device to vascularize to form vascularized tissue chambers within the device. The method generally includes transplanting insulin-producing cells into the vascularized tissue chambers of the device. The method generally includes allowing the transplanted insulin-producing cells to engraft within the vascularized tissue chambers. The method generally includes permitting the engrafted insulin-producing cells to sense blood glucose levels and secrete insulin in response thereto, thereby providing stable glycemic control. The method generally includes assessing quality of life of the patient using a validated psychological assessment instrument to determine a measurable reduction in diabetes-related distress.
[0011] Certain aspects of the present disclosure provide a method for treating diabetes and reducing diabetes-related distress in a patient. The method generally includes surgically implanting a cell pouch bio-hybrid organ in the patient, wherein the cell pouch bio-hybrid organ comprises an implantable macro-encapsulation device. The method generally includes permitting vascularized tissue chambers to form within the cell pouch bio-hybrid organ through integration with host tissue of the patient. The method generally includes transplanting a therapeutically effective number of cells capable of producing insulin into the vascularized tissue chambers. The method generally includes enabling the transplanted cells to secrete insulin in response to blood glucose levels of the patient to achieve glycemic control. The method generally includes evaluating a reduction in at least one of diabetes-related distress or fear of hypoglycemia or hypoglycemia unawareness using a validated assessment instrument.
[0012] The foregoing summary, as well as the following detailed description, is not intended to be exhaustive or to limit the disclosure to the precise forms disclosed. The features described are indicative of but a few of the various ways in which the principles of the disclosure may be employed. Other implementations are also described and recited herein.Attorney Docket No.: 410694-504001WQBRIEF DESCRIPTION OF THE DRAWINGS
[0013] For the purpose of illustration, certain embodiments of the present invention are shown in the drawings described below. It should be understood, however, that the invention is not limited to the precise arrangements, dimensions, and instruments shown. In the drawings:
[0014] FIG. 1 provides a schematic illustration of the steps in a method for enhancing the quality of life in a patient with type 1 diabetes through the implantation of a cell pouch biohybrid organ.
[0015] FIG. 2 provides bar graphs showing composite measures of islet graft function in study participants following transplantation of islet cells into vascularized Cell Pouch bio-hybrid organs. The top panel shows BETA-2 scores for twelve study participants, and the lower panel shows BETA scores for twelve study participants, each score providing an assessment of posttransplant beta-cell graft function.
[0016] FIG. 3 provides a longitudinal line graph of Hemoglobin A1c (HbA1c) values measured in the twelve study participants during the clinical study described in Example 1. HbA1c is plotted as a percentage over sequential study measurements for each participant, and a shaded region identifies the recommended HbA1c range for patients with type 1 diabetes. The graph shows that all twelve study participants achieved an HbA1c of less than 7.0%.
[0017] FIG. 4 provides a paired bar graph showing Clarke Hypoglycemia Index scores for twelve study participants at initial screening and at 180 days after treatment with transplanted islet cells in vascularized Cell Pouch bio-hybrid organs. For each participant, a first bar represents the initial screening score and an adjacent second bar represents the day-180 post-treatment score, with the bars indicating hypoglycemia awareness classifications, including aware, reduced awareness, and unaware.
[0018] FIG. 5 provides a paired bar graph showing total Hypoglycemia Fear Survey-ll (HFS-II) scores for twelve study participants at patient screening and at 180 days after the second treatment or transplantation time point, identified in the figure as “Post Tx #2.” For each participant, a first bar represents the patient-screening total score and an adjacent second bar represents the 180-day post-Tx#2 total score. The total HFS-II score reflects summed item scores across the Worry and Behavior subscales, with higher scores indicating greater fear of hypoglycemia.
[0019] FIG. 6 provides a paired bar graph showing Diabetes Distress Scale (DDS) total scores for twelve study participants at patient screening and at 180 days after the second treatment or transplantation time point, identified in the figure as “Post Tx #2.” For each participant, a first bar represents the patient-screening DDS total score and an adjacent secondAttorney Docket No.: 410694-504001WQbar represents the 180-day post-Tx#2 DDS total score. The DDS is a 17-item patient-reported questionnaire in which participants rate diabetes-management-related distress on a six-point scale, with higher scores indicating greater distress.
[0020] It should be understood that while different depictions, plots and / or colors with images could be sometimes used in some of the figures above to describe different embodiments and different aspects of the technology, any aspect from any figure can be intercombined with any aspect from any other figures.DETAILED DESCRIPTION
[0021] In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and clauses are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein. It may be evident, however, that the present invention may be practiced without these specific details. In other instances, well-known structures and devices are shown in block diagram form in order to facilitate describing the present invention. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present disclosure is defined by the appended claims.DEFINITIONS
[0022] For convenience, the meaning of some terms and phrases used in the specification, examples, and appended claims, are provided below. Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below. The definitions are provided to aid in describing particular embodiments, and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. If there is an apparent discrepancy between the usage of a term in the art and its definition provided herein, the definition provided within the specification shall prevail.Attorney Docket No.: 410694-504001WO
[0023] As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the content clearly dictates otherwise. For example, reference to "a cell" includes a combination of two or more cells, and the like.
[0024] As used herein, the term "approximately" or "about" in reference to a value or parameter are generally taken to include numbers that fall within a range of 5%, 10%, 15%, or 20% in either direction (greater than or less than) of the number unless otherwise stated or otherwise evident from the context (except where such number would be less than 0% or exceed 100% of a possible value). As used herein, reference to "approximately" or "about" a value or parameter includes (and describes) embodiments that are directed to that value or parameter. For example, description referring to "about X" includes description of "X".
[0025] As used herein, the term “or” means “and / or.” The term "and / or" as used in a phrase such as "A and / or B" herein is intended to include both A and B; A or B; A (alone); and B (alone). Likewise, the term "and / or" as used in a phrase such as "A, B, and / or C" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0026] As used herein, the term "comprising" means that other elements can also be present in addition to the defined elements presented. The use of "comprising" indicates inclusion rather than limitation.
[0027] The term "consisting of" refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.
[0028] As used herein the term "consisting essentially of' refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.
[0029] The term "statistically significant" or "significantly" refers to statistical significance and generally means a two standard deviation (2SD) or greater difference.
[0030] As used herein, the term "subject" refers to a mammal, including but not limited to a dog, cat, horse, cow, pig, sheep, goat, chicken, rodent, or primate. Subjects can be house pets (e.g., dogs, cats), agricultural stock animals (e.g., cows, horses, pigs, chickens, etc.), laboratory animals (e.g., mice, rats, rabbits, etc ), but are not so limited. Subjects include human subjects. The human subject may be a pediatric, adult, or a geriatric subject. The human subject may be of either sex.Attorney Docket No.: 410694-504001WQ
[0031] As used herein, the terms "effective amount" and “therapeutically-effective amount” include an amount sufficient to prevent or ameliorate a manifestation of disease or medical condition, such as type I diabetes. It will be appreciated that there will be many ways known in the art to determine the effective amount for a given application. For example, the pharmacological methods for dosage determination may be used in the therapeutic context. In the context of therapeutic or prophylactic applications, the amount of a composition administered to the subject will depend on the type and severity of the disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. The compositions can also be administered in combination with one or more additional therapeutic compounds.
[0032] As used herein, the terms “treat,” “treatment,” “treating,” or “amelioration” when used in reference to a disease, disorder or medical condition, refer to therapeutic treatments for a condition, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of a symptom or condition. The term “treating” includes reducing or alleviating at least one adverse effect or symptom of a condition. Treatment is generally “effective” if one or more symptoms or clinical parameters are improved. Alternatively, treatment is “effective” if the progression of a condition is reduced or halted. That is, “treatment” includes not just the improvement of symptoms or clinical parameters, but also a cessation or at least slowing down of progression or worsening of symptoms that would be expected in the absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of the deficit, stabilized ( / .e., not worsening) state of the disease, disorder or medical condition, e.g., type I diabetes, delay or slowing down of the disease, disorder or medical condition, e.g., type I diabetes, and an increased lifespan as compared to that expected in the absence of treatment. In some embodiments, treatment comprises transplantation of cells (e.g., therapeutic cells, e.g., islets) to a patient (e.g., a diabetic patient), to obtain a treatment benefit enumerated herein. The treatment can be to cure, heal, alleviate, delay, prevent, relieve, alter, remedy, ameliorate, palliate, improve, or affect a disease, disorder, or condition (e.g., diabetes), the symptoms of a disease, disorder, or condition (e.g., diabetes), ora predisposition toward a disease, disorder, or condition (e.g., diabetes). In some embodiments, the disease, disorder, or condition needing treatment is diabetes (e.g., type 1 diabetes). In some embodiments, the disease, disorder, or condition needing treatment is type 1 diabetes (T1 DM).Attorney Docket No.: 410694-504001WO
[0033] The terms “decrease”, “reduced”, “reduction”, or “inhibit” are all used herein to mean a decrease by a statistically significant amount. In some embodiments, “reduce,” “reduction" or “decrease" or “inhibit” typically means a decrease by at least 10% as compared to a reference level (e.g., the absence of a given treatment or agent) and can include, for example, a decrease by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99% , or more. As used herein, “reduction” or “inhibition” does not encompass a complete inhibition or reduction as compared to a reference level. “Complete inhibition” is a 100% inhibition as compared to a reference level. A decrease can be preferably down to a level accepted as within the range of normal for an individual without a given disorder.
[0034] The terms “increased”, “increase”, “enhance”, or “activate” are all used herein to mean an increase by a statically significant amount. In some embodiments, the terms “increased”, “increase”, “enhance”, or “activate” can mean an increase of at least 10% as compared to a reference level, for example an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% increase or any increase between 10-100% as compared to a reference level, or at least about a 2-fold, or at least about a 3-fold, or at least about a 4-fold, or at least about a 5-fold or at least about a 10-fold increase, or any increase between 2-fold and 10-fold or greater as compared to a reference level. In the context of a marker or symptom, a “increase” is a statistically significant increase in such level.
[0035] As used herein, "macro-encapsulation device" means any implantable structure, scaffold, or pouch configured to house therapeutic cells, tissues, or agents while permitting the ingress of vascular structures and the egress of therapeutic products, such as insulin, and is not limited to a specific geometry, size, or material composition.
[0036] As used herein, "cell pouch bio-hybrid organ" means a macro-encapsulation device that has been implanted and integrated with host tissue to form a vascularized environment capable of supporting the long-term survival, engraftment, and physiological function of transplanted therapeutic cells.
[0037] As used herein, "insulin-producing cells" means any biological cells, whether primary, derived, or engineered, capable of synthesizing and secreting insulin in response toAttorney Docket No.: 410694-504001WQphysiological signals, including but not limited to purified human donor islets, stem cell-derived beta cells, and xenogeneic islet cells.
[0038] As used herein, "therapeutically effective amount" means a quantity of cells or therapeutic agents sufficient to achieve a desired physiological or clinical outcome, such as stable glycemic control, insulin independence, ora measurable reduction in diabetes-related distress, which may encompass, for example, a borderline mass of approximately 3,000 to 5,000 islet equivalent cells per kilogram of patient body weight.
[0039] As used herein, "vascularized tissue chambers" means spaces, voids, or compartments within an implanted device that have been permeated, lined, or surrounded by host blood vessels and connective tissue, providing a nutrient-rich and oxygenated environment for subsequent cell engraftment.
[0040] As used herein, "validated psychological assessment instrument" means any standardized questionnaire, survey, or clinical tool used to quantify psychological, emotional, or cognitive states, including but not limited to the Diabetes Distress Score (DDS), the Hypoglycemia Fear Survey-ll (HFS-II), and the Clarke Hypoglycemia Awareness Scale.
[0041] As used herein, "glycemic control" means the maintenance of blood glucose levels within a target physiological range, which may be evidenced by clinical markers such as Hemoglobin A1c (HbA1c) levels below a specified threshold (e.g., less than 7.0 percent), increased Time in Range (TIR), or sustained C-peptide levels (e.g., at least 0.3 ng / mL) indicating endogenous insulin production.
[0042] As used herein, the term “diabetes” or “diabetes mellitus” refers to a medical condition characterized by elevated levels of plasma glucose (hyperglycemia) in the fasting state. Chronic diabetes conditions include type 1 diabetes and type 2 diabetes. In type 1 diabetes (T1 DM), or insulin-dependent diabetes mellitus (IDDM), patients can produce little or no insulin (i.e., the hormone capable of regulating glucose utilization). In type 2 diabetes (T2 DM), or noninsulin-dependent diabetes mellitus (NIDDM), patients can produce insulin and may even exhibit hyperinsulinemia (i.e., plasma insulin levels that are the same or elevated in comparison with non-diabetic subjects), while at the same time demonstrating hyperglycemia. Potentially reversible diabetes conditions include prediabetes (i.e., a condition in which plasma glucose levels may be higher than normal, but not high enough to be classified as diabetes), as well as gestational diabetes (i.e., a condition which can occur during pregnancy, but resolves after the baby is delivered). In some embodiments, the diabetes is type 1 diabetes. In some embodiments, the diabetes is type 1 diabetes mellitus with hypoglycemia unawareness.Table 1 provides a comparison of some different types of diabetes.Attorney Docket No.: 410694-504001WOTable 1 - Comparative Characteristics of Some Diabetes Types Category Type / Subtype Notes / Examples Type 1 Diabetes Mellitus Classic Type 1 Autoimmune destruction of (3-cel Is, typical onset in childhood, adolescence Latent Autoimmune Diabetes in Adult(LADA) Slower onset, adultIdiopathic Type 1 Non-autoimmune, unknown cause Type 2 Diabetes Mellitus Classic Type 2 Insulin resistance, often with obesity Non-obese Type 2 Occurs in non-obese individuals Ketosis Type 2 More common in African descent, can present with ketoacidosisHybrid Types Diabetes Slowly Evolving Immune-MediatedDiabetes Features of both type 1 and type 2 Ketosis-prone Type 2 (Overlap) See aboveMonogenic Diabetes Maturity-Onset Diabetes of the Autosomal dominant, young onset, Syndromes Young (MODY) multiple subtypesMODY1 (HNF4A)MODY2 (GCK)MODY3 (HNF1A) Most common MODYMODY4 (PDX1)MODY5 (HNF1B) Renal cysts / abnormalities MODY6 (NEUROD1)MODY7 (KLF11)MODY8 (CEL) Paracrine exocrine dysfunction MODY9 (PAX4)MODYW (INS) Insulin gene mutationMODY11 (BLK)MODY12 (ABCC8) Potassium channel defect MODY13 (KCNJ11) Potassium channel defect MODY14 (APPL1) Recently identifiedNeonatal Diabetes Diagnosed <6 months old Permanent Neonatal DiabetesMellitus (PNDM) LifelongTransient Neonatal Diabetes Mellitus(TNDM) Resolves but may recur Maternally Inherited Diabetes and Mitochondrial DNA mutation;Deafness (MIDD) aka Mitochondrial Diabetes Diseases of the ExocrinePancreas Pancreatitis-Related Diabetes After acute / chronic pancreatitis Pancreatectomy-Induced Diabetes After surgical removal Pancreatic Cancer-Related Diabetes Associated with pancreatic tumors Cystic Fibrosis-Related Diabetes Due to OFHemochromatosis-Related Diabetes Iron overloadEndocrine Disorders Cushing’s Syndrome-RelatedCausing Diabetes Diabetes Excess cortisolAcromegaly-Related Diabetes Excess growth hormone Glucagonoma-Related Diabetes Excess glucagon Pheochromocytoma-Related Diabetes Excess catecholaminesHyperthyroidism-Induced Diabetes Excess thyroid hormoneAttorney Docket No.: 410694-504001WODrug or Chemical-InducedDiabetes Glucocorticoid-Induced Diabetes Steroid medications Antipsychotic-Induced Diabetes Clozapine, olanzapine, quetiapine Statin-Induced Diabetes Cholesterol-lowering drugsBeta-Blocker-lnduced Diabetes Blood pressure drugsThiazide Diuretic-Induced Diabetes Diuretic medications Antiretroviral-Induced Diabetes HIV meds (protease inhibitors, NRTIs) Immunosuppressant-InducedDiabetes mTOR inhibitors (post-transplant) Tyrosine Kinase Inhibitor-InducedDiabetes Cancer therapiesInterferon-Alpha-lnduced Diabetes ImmunotherapyGenetic SyndromesAssociated with Diabetes Down Syndrome-Related DiabetesKlinefelter Syndrome-RelatedDiabetesTurner Syndrome-Related DiabetesWolfram Syndrome (DIDMOAD) Diabetes insipidus, DM, optic atrophy, deafnessFriedreich Ataxia-Related DiabetesHuntington Disease-Related DiabetesLaurence-Moon-Biedl Syndrome- Related DiabetesMyotonic Dystrophy-Related DiabetesPorphyria-Related DiabetesPrader-Willi Syndrome-RelatedDiabetesInfection-Related Diabetes Congenital Rubella Syndrome- Related DiabetesCytomegalovirus-Related DiabetesOther Categories Gestational Diabetes Mellitus (GDM) Diagnosed during pregnancy Malnutrition-Related Diabetes Mellitus Rare, ICD-11 category Metabolic Syndrome-Associated With abdominal obesity, dyslipidemia, Diabetes hypertensionStress-Induced Hyperglycemia Transient during acute illnessUnclassified Diabetes Cannot be clearly categorized
[0043] In some embodiments, the system of the present disclosure is transplanted with insulin-producing cells and used to treat patients afflicted with, or at risk of, a diabetic disease selected from the group consisting of: Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus; Hybrid Types Diabetes; Monogenic Diabetes Syndromes; Neonatal Diabetes; Diseases of the Exocrine Pancreas; Endocrine Disorders Causing Diabetes; Drug or Chemical-Induced Diabetes; Genetic Syndromes Associated with Diabetes; Infection- Related Diabetes; and other categories of diabetes.
[0044] In some embodiments, the Type 1 Diabetes Mellitus is selected from the group consisting of: Classic Type 1; Latent Autoimmune Diabetes in Adult (LADA); and Idiopathic Type 1. In some embodiments, the Type 2 Diabetes Mellitus is selected from the groupAttorney Docket No.: 410694-504001WOconsisting of: Classic Type 2; Non-obese Type 2; and Ketosis Type 2. In some embodiments, the Hybrid Types Diabetes is selected from the group consisting of: Slowly Evolving Immune-Mediated Diabetes and Ketosis-prone Type 2. In some embodiments, the Monogenic Diabetes Syndromes is selected from the group consisting of: Maturity-Onset Diabetes of the Young (MODY); M0DY1 (HNF4A); M0DY2 (GCK); M0DY3 (HNF1A); M0DY4 (PDX1); M0DY5 (HNF1B); M0DY6 (NEUROD1); M0DY7 (KLF11); MODY8 (CEL); M0DY9 (PAX4); MODY10 (INS); MODY11 (BLK); MODY12 (ABCC8); MODY13 (KCNJ11); and MODY14 (APPL1). In some embodiments, the Neonatal Diabetes is selected from the group consisting of: Permanent Neonatal Diabetes Mellitus (PNDM); Transient Neonatal Diabetes Mellitus (TNDM); and Maternally Inherited Diabetes and Deafness (MIDD). In some embodiments, the Diseases of the Exocrine Pancreas is selected from the group consisting of: Pancreatitis-Related Diabetes; Pancreatectomy-Induced Diabetes; Pancreatic Cancer-Related Diabetes; Cystic Fibrosis-Related Diabetes; and Hemochromatosis-Related Diabetes. In some embodiments, the Endocrine Disorders Causing Diabetes is selected from the group consisting of: Cushing’s Syndrome-Related Diabetes; Acromegaly-Related Diabetes; Glucagonoma-Related Diabetes; Pheochromocytoma-Related Diabetes; and Hyperthyroidism-Induced Diabetes. In some embodiments, the Drug or Chemical-Induced Diabetes is selected from the group consisting of: Glucocorticoid-Induced Diabetes; Antipsychotic-Induced Diabetes; Statin- Induced Diabetes; Beta-Blocker-lnduced Diabetes; Thiazide Diuretic-Induced Diabetes; Antiretroviral-Induced Diabetes; Immunosuppressant-Induced Diabetes; Tyrosine Kinase Inhibitor-Induced Diabetes; and Interferon-Alpha-lnduced Diabetes. In some embodiments, the Genetic Syndromes Associated with Diabetes is selected from the group consisting of: Down Syndrome-Related Diabetes; Klinefelter Syndrome-Related Diabetes; Turner Syndrome-Related Diabetes; Wolfram Syndrome (DIDMOAD); Friedreich Ataxia-Related Diabetes; Huntington Disease-Related Diabetes; Laurence-Moon-Biedl Syndrome-Related Diabetes; Myotonic Dystrophy- Related Diabetes; Porphyria-Related Diabetes; and Prader-Willi Syndrome-Related Diabetes. In some embodiments, the Infection- Related Diabetes is selected from the group consisting of:Congenital Rubella Syndrome-Related Diabetes and Cytomegalovirus-Related Diabetes. In some embodiments, the other categories of diabetes are selected from the group consisting of: Gestational Diabetes Mellitus (GDM); Malnutrition-Related Diabetes Mellitus; Metabolic Syndrome-Associated Diabetes; Stress-Induced Hyperglycemia; and Unclassified Diabetes.
[0045] In some embodiments of the methods disclosed herein, the patient has type 1 diabetes mellitus with hypoglycemia unawareness. In some embodiments, the patient has type 1 diabetes mellitus with hypoglycemia unawareness as measured by: (i) a Clarke reducedAttorney Docket No.: 410694-504001WOawareness score of 3, 4, 5, or more (e.g., about 4 or more); (ii) a HYPO score greater than or equal to the 90th percentile (e.g., about 1047) during the screening period and within the last 6 months; (iii) one or more swings in blood glucose despite diabetes therapy as defined by an LI score greater than or equal to the 90th percentile (e.g., about 433 mmol / L2 / h wk-1) during the screening period and / or within the 6 months prior to treatment; and / or (iv) a composite Clarke score of about 4 or more and a HYPO score greater than or equal to about the 75th percentile and a LI greater than or equal to about the 75th percentile (e.g., about 329) during the screening period and / or within the 6 months prior to treatment. In some embodiments, the patient has a history of severe hypoglycemic episodes. In some embodiments, the patient has required insulin for about 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more years (e.g., at least about 5 years). In some embodiments, the patient is between about 18 and 65 years of age.
[0046] As used herein, the term “severe hypoglycemia” or “severe hypoglycemic episode” encompasses at least one event with at least one of the following symptoms: memory loss; confusion; uncontrollable behavior; irrational behavior; unusual difficulty in awakening; suspected seizure; seizure; loss of consciousness; or visual symptoms, in which the patient was unable to treat him / herself and which was associated with either a blood glucose level<54 mg / dL [3.0 mmol / L] or prompt recovery after oral carbohydrate, IV glucose, or glucagon administration. In addition, in some embodiments, composite indices of hypoglycemia frequency, severity, and / or symptom recognition may be assessed, e.g., to determine a severe hypoglycemic episode, by a Clarke survey and / or HYPO score.
[0047] In some embodiments, a Clarke survey, as described in, e.g., Clarke et al.(1995),4is used alone or in combination with another method (e.g., HYPO score) to assess awareness of hypoglycemia. In some embodiments, a Clarke survey involves subject completion of eight questions characterizing the subject's exposure to episodes of moderate and severe hypoglycemia. In some embodiments, a Clarke survey further evaluates the subject’s glycemic threshold for, and symptomatic responses to, hypoglycemia. In some embodiments, the eight question survey is scored according to an answer key that gives a total score between 0 and 7 (most severe). In some embodiments, a score of 4 or more indicates reduced and / or impaired awareness of hypoglycemia and / or increased risk for severe hypoglycemic events.
[0048] In some embodiments, a HYPO score, as described in, e.g., Ryan etal. (2004),5is used alone or in combination with another method (e.g., Clarke survey) to assess awareness of hypoglycemia. In some embodiments, a HYPO score involves subject recording of blood glucose readings and hypoglycemic events (blood glucose (BG) <3.0 mmol / L [54 mg / dL]) over aAttorney Docket No.: 410694-504001WO4-week period and recall of all severe hypoglycemic episodes in the previous 12 months. In some embodiments, calculation of a HYPO score comprises at least 28 days of capillary blood glucose tests within a 35-day period with at least four tests per day. In some embodiments, a HYPO score greater than or equal to the 90th percentile (1047) of values derived from an unselected group of type 1 diabetes patients indicates severe problems with hypoglycemia.
[0049] In some embodiments, a mixed meal tolerance test (MMTT) is performed on a patient, e.g., prior to treatment, e.g., to assess islet function and / or determine basal (fasting), stimulated glucose, and / or C-peptide levels. In some embodiments, the patient has a blood glucose level of 70-180 mg / dL (3.89-10mmol / L) prior to the meal test. In some embodiments, basal glucose and / or C-peptide levels in the patient are determined prior to the meal test. In some embodiments, the meal test comprises administration of a standardized meal to the patient. An exemplary standardized meal is Boost® High Protein Drink (or a nutritionally equivalent substitute). In some embodiments, the standardized meal is and / or the meal test comprises Boost® 6 ml_ / kg body weight (to a maximum of 360 mL). In some embodiments, the patient is administered Boost® 6 ml_ / kg body weight (to a maximum of 360 mL) to consume in, e.g., about 5 minutes, starting at time 0. In some embodiments, blood samples for stimulated glucose, C-peptide, and / or insulin levels are then drawn from the patient (e.g., at time 15, 30, 45, 60, 90, 120, 180, and / or 240 minutes). In some embodiments, the standardized meal and / or meal test provides up to 50 carbohydrates without insulin treatment during an about 1, 2, 3, 4, or 5 hour test (e.g., an about 2 or 4 hour test). In some embodiments, the standardized meal and / or meal test causes short term hypoglycemia in the patient. In some embodiments, immediately after the meal test is completed, an adequate insulin dose is administered to the patient, e.g., to ensure proper glycemic control.
[0050] In some embodiments of the methods disclosed herein, the patient has less than about 0.3 ng / mL C-peptide in a serum sample prior to treatment in response to a mixed meal tolerance test (e.g., a meal test using Boost® 6 mL / kg body weight to a maximum of 360 mL). In some embodiments, the patient has less than about 0.3 ng / mL C-peptide in a serum sample prior to treatment in response to a mixed meal tolerance test (e.g., a meal test using Boost® 6 mL / kg body weight to a maximum of 360 mL) as measured during an about 1, 2, 3, 4, or 5 hour test (e.g., an about 2 hour test). In some embodiments, the patient is restored to normoglycemia.
[0051] In some embodiments, a patient is assessed for glycemic control and / or glycemic lability. The term “glycemic control,” as used herein, refers to the typical levels of blood glucose in a subject with diabetes, e.g., type 1 diabetes. Exemplary glycemic biomarkers that may beAttorney Docket No.: 410694-504001WOused to monitor glycemic control include, but are not limited to, glycated hemoglobin (i.e., hemoglobulin A1 c (HbA1 c)), fructosamine, glycated albumin (GA), and 1,5-anhydroglucitol (1,5-AG). In some embodiments, glycemic control is monitored in a patient, e.g., by measuring levels of HbA1 c and / or one or more alternate glycemic biomarkers.
[0052] The term “glycemic lability,” as used herein, refers to a lability index (LI) calculated based on change in a patient’s glucose levels overtime. Typically, a LI requires 4 or more daily capillary blood glucose measurements over a 4-week period and is calculated as the sum of all the squared differences in consecutive glucose readings divided by how far apart the readings were determined (range 1 to 12 hours) in mmol / L2 / h wk-1. In some embodiments, a LI greater than or equal to the 90th percentile (433 mmol / L2 / h wk-1) of values derived from an unselected group of type 1 diabetes patients indicates severe glycemic lability.
[0053] In some embodiments of the methods disclosed herein, at least some of the cells infused in the chamber express insulin. In some embodiments, the cells and / or the insulinexpressing cells are administered at a borderline mass of about 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, or 4000 lEQ / kg, or greater. In some embodiments, the cells and / or the insulin-expressing cells are administered at a borderline mass of about 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, or 5000 lEQ / kg, or greater. In some embodiments, at least about 60%, 65%, 70%, 75%, 80%, 85%, or 90% (e.g., at least 70%) of the cells infused in the chamber are purified islets. In some embodiments, at least about 70%, 75%, 80%, 85%, or 90% (e.g., at least 80%) of the cells infused in the chamber are viable islets.
[0054] As used herein, the term “I EQ” or “islet equivalent,” refers to volume of islet cells equal to that of a sphere having a 150 pm diameter. The term “lEQ / kg” refers to the number of islet equivalents administered per kilogram of a patient’s body weight.
[0055] As used herein, the term “purified islet” refers to one or more than one islet cell substantially free from other tissue naturally found around the islets, e.g., acinar tissue. In some embodiments, at least about 70% of the cells infused in the chamber are purified islets. Without wishing to be bound by theory, a large amount of acinar tissue surrounding islets may affect islet engraftment when competing for oxygen and nutrients, may result in the release of pancreatic enzymes, and / or may potentiate islet damage and / or inflammatory reactions. In some embodiments, islets with >70% purity are infused into the chamber. In some embodiments, islets with >90% purity are infused into the chamber. In some embodiments, islets with 70-90% purity are infused into the chamber. In some embodiments, islets with different purities are infused into separate chambers of the device.Attorney Docket No.: 410694-504001WQ
[0056] Methods of quantifying the number or percentage of islets in an islet preparation are known in the art and described in, e.g., Papas etal. (2009).6An exemplary method is manual, visual counting of islet equivalents (I EQ) under a light microscope following dithizone (DTZ) staining to determine the total volume of islet tissue and its purity. Exemplary methods for estimating the total number of cells and / or volume of tissue in a preparation include measurements of intracellular deoxyribonucleic acid (DNA), cellular nuclei counts, large particle flow cytometry, and packed tissue volume; however, such methods may not provide islet- or b-cell specific information, so may require an independent estimate of the purity (fractional volume of islet tissue or b-cells). Such estimates can be obtained using a variety of methods, including, but not limited to, morphological analysis with electron and / or light microscopy, immunohistochemistry with laser scanning confocal microscopy, and laser scanning cytometry. See, e.g., Colton et al. (2007).7
[0057] As used herein, the term “viable islet” refers to one or more than one islet cell with sufficient membrane integrity as determined by, e.g., a dye exclusion assay. An exemplary dye exclusion assay is fluorescein diacetate / propidium iodide (FDA / PI). See, e.g., Papas etal. (2009).8In some embodiments, at least about 80% of the cells infused in the chamber are viable islets.
[0058] In some embodiments, the cells are purified from a pellet prior to administration. In some embodiments, the pellet has a volume of less than about 30, 25, 20, 15, 12.5, 10.5, or 7.5 mL (e.g., less than about 10.5 mL). In some embodiments, the pellet has a volume of less than about 10.5 mL. In some embodiments, the cells are infused in the chamber about 4-24 weeks after implanting the device. In some embodiments, the cells are infused in the chamber about 4, 5, 6, 7, 8, 9, or 10 weeks after implanting the device. In some embodiments, the cells are infused in the chamber about 6 weeks after implanting the device.
[0059] In some embodiments, the methods disclosed herein further comprise administering immunosuppression prior to and / or after infusing the chamber with cells. In some embodiments, the immunosuppression is administered prior to infusion. In some embodiments, the immunosuppression is administered for at least 3, 4, 5, 6, 7, 8, 9, or 10 weeks prior to infusion. In some embodiments, the immunosuppression is administered for at least 3, 4, 5, or 6 weeks prior to infusion. In some embodiments, the immunosuppression is administered for at least 6 weeks prior to infusion. In some embodiments, the immunosuppression is administered after infusion. In some embodiments, the immunosuppression is administered for about 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 days after infusion. In some embodiments, the immunosuppression is administered for about 7 days after infusion.Attorney Docket No.: 410694-504001WQ
[0060] Unless otherwise defined herein, scientific and technical terms used in connection with the present application shall have the meanings that are commonly understood by those of ordinary skill in the art to which this disclosure belongs. It should be understood that this invention is not limited to the particular methodology, protocols, animal models, (engineered or genetically modified) cells, organoids, constructs, vectors, carriers, adjuvants, compounds, drug delivery system, antibodies and derivatives, vaccines, and reagents, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention, which is defined solely by the claims. Definitions of common terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy;9The Encyclopedia of Molecular Cell Biology and Molecular Medicine;10Molecular Biology and Biotechnology: a Comprehensive Desk Reference;11Immunology;12Janeway's Immunobiology;13Lewin's Genes XI;14Molecular Cloning: A Laboratory Manual.;15Basic Methods in Molecular Biology;16Laboratory Methods in Enzymology;17Current Protocols in Molecular Biology (CPMB);18Current Protocols in Protein Science (CPPS);19and Current Protocols in Immunology (CPI).20
[0061] In some embodiments of any of the aspects, the disclosure described herein does not concern a process for cloning human beings, processes for modifying the germ line genetic identity of human beings, uses of human embryos for industrial or commercial purposes or processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes.
[0062] Other terms are defined herein within the description of the various aspects of the invention.CELL POUCH BIO-HYBRID ORGAN
[0063] In contrast to conventional systems that rely on exogenous insulin injections and continuous manual monitoring — which often fail to prevent severe hypoglycemic events and impose a psychological burden — the present disclosure provides a macro-encapsulation device seeded with insulin-producing cells, which results in the restoration of endogenous, regulated insulin secretion and facilitates a measurable improvement in both physiological stability and patient quality of life.
[0064] The core principle of the present disclosure relies on a dual-mechanism approach that bridges physiological control and psychological relief. Physiologically, the method utilizes a defined, two-stage clinical protocol. Initially, the macro-encapsulation deviceAttorney Docket No.: 410694-504001WQis surgically implanted and left in situ for a vascularization period, typically approximately 6 to 8 weeks. This period allows the device to integrate with the host tissue, forming a vascularized scaffold and mitigating the foreign body response or fibrosis associated with conventional implants. Subsequently, under an appropriate immunosuppression regimen (utilizing agents such as anti-thymocyte globulin, basiliximab, etanercept, mycophenolate mofetil, or tacrolimus to prevent T-cell activation and graft rejection), therapeutic cells are transplanted into these preformed vascularized tissue chambers. The pre-vascularized environment supports the successful engraftment and long-term survival of the transplanted cells.
[0065] Once engrafted, these cells function as a replacement bio-hybrid organ. They sense real-time blood glucose levels and secrete insulin accordingly. This dynamic, physiological responsiveness restores endogenous insulin production, stabilizes glycemic control, increases Time in Range (TIR), and reduces the incidence of hyperglycemic and severe hypoglycemic events. The physiological success of the graft is continuously monitored using biomarkers such as C-peptide levels and composite metrics like BETA and BETA-2 scores.
[0066] Psychologically, this newfound physiological stability directly translates to an enhancement in the patient's emotional health. By eliminating the pervasive fear of sudden hypoglycemic episodes and reducing the need for constant, vigilant self-monitoring, the present methods measurably reduce diabetes-related distress, anxiety, and fear. The efficacy of this dual mechanism is quantified using validated psychological instruments, demonstrating a holistic treatment paradigm. While primarily described in the context of treating type 1 diabetes mellitus with hypoglycemia unawareness, the principles of the present disclosure are broadly applicable to a wide range of diabetes types and subtypes where islet cell function is compromised. Having described the general principles and definitions of the disclosure, specific, non-limiting embodiments will now be described in greater detail.
[0067] FIG. 1 is a flowchart illustrating a method for improving emotional health in a patient with diabetes through the use of a cell pouch bio-hybrid system, according to an embodiment. At step 100, the cell pouch bio-hybrid system may be implanted in the patient. This system may serve as an implantable device designed to promote vascularization and tissue integration, reduce fibrosis, and create a suitable environment for cell transplantation. The cell pouch bio-hybrid system may incorporate with tissue and form highly vascularized tissue chambers, facilitating the transplantation and function of cells expressing insulin. The cells expressing insulin may be therapeutic cells that produce and release biologically active molecules, potentially providing insulin independence and contributing to the treatment of diabetes.Attorney Docket No.: 410694-504001WO
[0068] Subsequently, at step 102, vascularized tissue chambers are permitted to form within the cell pouch bio-hybrid organ through integration with host tissue of the patient. This integration transforms the implantable macro-encapsulation device into a vascularized scaffold, preparing the device for the subsequent introduction and long-term survival of transplanted cells. This step may be essential for ensuring that the cell pouch bio-hybrid system, which is an implantable device, integrates effectively with the patient's tissue. The integration may promote vascularization and tissue integration, which can reduce fibrosis and create a suitable environment for cell transplantation. The cell pouch bio-hybrid system may incorporate with tissue to form highly vascularized tissue chambers, facilitating the transplantation and function of cells expressing insulin. This process may be essential for the long-term survival and function of therapeutic cells, which are intended to produce and release biologically active molecules for the treatment of diabetes. The maintenance of the cell pouch bio-hybrid system until sufficient vascularization is achieved may be a step in the method, as it allows for the establishment of a system that supports the transplantation and integration of cells expressing insulin. This step may also contribute to achieving insulin independence and improving the patient's emotional health, as the successful integration and function of the cell pouch bio-hybrid system can enhance the patient's well-being. The process of maintaining the cell pouch biohybrid system may involve allowing the infiltration of vascular and connective tissues, which can ensure successful implantation and function of the therapeutic cells.
[0069] Following this action, at step 104, a therapeutically effective number of cells capable of producing insulin is transplanted into the vascularized tissue chambers. The therapeutically effective amount of cells may include approximately 3,000 to 5,000 islet equivalent cells per kilogram of patient body weight. This therapeutic dose of insulin-producing islet cells is delivered into the pre-vascularized environment to support engraftment and restore endogenous insulin production. The cells expressing insulin, which may include donor cells, stem cell-derived cells, or xenogeneic cells, can produce and release biologically active molecules necessary for the treatment of diabetes. The transplanted cells are enabled to secrete insulin in response to blood glucose levels of the patient to achieve glycemic control. By sensing real-time blood glucose levels and secreting insulin accordingly, the transplanted cells function as a bio-hybrid organ, stabilizing blood glucose levels and reducing the occurrence of severe hypoglycemic events. The success of the transplantation may be defined in terms of insulin independence, C peptide secretion, or glycemic control. Additionally, beta scores, which may include BETA or BETA-2 scores, can be used to assess the engraftment and function of the transplanted cells expressing insulin. These scores may serve as numericalAttorney Docket No.: 410694-504001WOassessments of beta cell function, which are crucial for evaluating the success of islet transplantation. The entire process may be designed to ensure the long-term survival and function of the therapeutic cells, ultimately contributing to the improved quality of life for the patient with diabetes.
[0070] Finally, at step 106, a reduction in at least one of diabetes-related distress, fear of hypoglycemia, or hypoglycemia unawareness is evaluated using a validated assessment instrument. As described in the section below, the validated assessment instrument may include at least one of a Diabetes Distress Score, a Hypoglycemia Fear Survey-ll, or a Clarke Hypoglycemia Awareness Scale. This evaluation confirms the psychological benefits of the treatment, demonstrating that the restored physiological control The improved emotional health of the patient may include an enhanced patient-reported quality of life score, an improved awareness of hypoglycemia, and an increased sensitivity to severe hypoglycemic symptoms. The overall approach may aim to improve the quality of life for patients with diabetes by providing insulin independence and enhancing emotional health, directly improves patient outcomes and quality of life.QUALITY OF LIFE ASSESSMENT
[0071] In the context of assessing the emotional health of a patient with diabetes, the process may involve evaluating the patient's emotional well-being at regular intervals. This assessment can be conducted using various scales and scores, such as the Clarke Hypoglycemia Awareness Scale, the Hypoglycemia Fear Survey-ll, or the Diabetes Distress Score.
[0072] These tools may provide insights into the patient's emotional state and help in understanding the impact of diabetes on their mental health. The assessment may aim to improve the patient's emotional health by enhancing their awareness of hypoglycemia, increasing their sensitivity to severe hypoglycemic symptoms, and improving their patient-reported quality of life score. The process may involve a comprehensive evaluation of the patient's emotional and mental health, which can contribute to achieving insulin independence and an overall improved quality of life. The assessment may be part of a broader strategy to provide insulin independence and emotional health, ultimately enhancing the patient's wellbeing.
[0073] Some embodiments of the technology described herein can be defined according to any of the following numbered illustrative clauses:Attorney Docket No.: 410694-504001WOClause 1. A method for enhancing quality of life in a patient with type 1 diabetes, comprising:implanting a cell pouch bio-hybrid organ in the patient;allowing the cell pouch bio-hybrid organ to become vascularized;transplanting islet cells into the vascularized cell pouch bio-hybrid organ; and assessing the diabetes-related distress and quality of life of the patient, wherein the patient experiences an improved glycemic control and / or reduce hypoglycemic events, andwherein the patient experiences a reduction in diabetes-related distress and an improvement in quality of life.Clause 2. A method for enhancing emotional health in a patient with type 1 diabetes, comprising:implanting a cell pouch bio-hybrid organ in the patient;allowing the cell pouch bio-hybrid organ to become vascularized;transplanting islet cells into the vascularized cell pouch bio-hybrid organ; and assessing the diabetes-related distress and quality of life of the patient, wherein the patient experiences a reduction in diabetes-related distress and an improvement in quality of life.Clause 3. The method of clauses 1 or 2, wherein the diabetes-related distress and quality of life of the patient is assessed using one or more patient-reported instrument.Clause 4. The method of clause 3, wherein the one or more patient-reported instrument is selected from the group consisting of: the Diabetes Distress Score (DDS), the Clarke Hypoglycemia Awareness Scale, and the Hypoglycemia FearSurvey-ll.Clause 5. The method of any one of clauses 1-4, wherein the patient experiences a reduction in fear of hypoglycemia.Clause 6. The method of any one of clauses 1-4, wherein the patient experiences an improvement in hypoglycemia awareness.Clause 7. The method of any one of clauses 1-4, wherein the patient experiences an increase in sensitivity to hypoglycemic symptoms.Clause 8. The method of any one of clauses 1-4, wherein the patient experiences a reduction in anxiety related to diabetes management.Clause 9. The method of any one of clauses 1-4, wherein the patient experiences a reduction in depression symptoms associated with diabetes.Attorney Docket No.: 410694-504001WO
[0074] Alternative embodiments of the technology described herein can be defined according to any of the following numbered illustrative clauses:Clause 1. A method for enhancing quality of life in a patient with diabetes, comprising:implanting a macro-encapsulation device in the patient;allowing the implanted device to vascularize to form vascularized tissue chambers within the device;transplanting insulin-producing cells into the vascularized tissue chambers of the device;allowing the transplanted insulin-producing cells to engraft within the vascularized tissue chambers;permitting the engrafted insulin-producing cells to sense blood glucose levels and secrete insulin in response thereto, thereby providing stable glycemic control; and assessing quality of life of the patient using a validated psychological assessment instrument to determine a measurable reduction in diabetes-related distress.Clause 2. The method of clause 1, wherein the macro-encapsulation device comprises a cell pouch bio-hybrid organ.Clause 3. The method of clause 1 , wherein allowing the implanted device to vascularize comprises a vascularization period of approximately 6 to 8 weeks.Clause 4. The method of clause 1, wherein the insulin-producing cells comprise purified human donor islets.Clause 5. The method of clause 1, wherein the insulin-producing cells comprise stem cell-derived cells.Clause 6. The method of clause 1 , wherein the insulin-producing cells comprise xenogeneic cells. Clause 7. The method of clause 1, wherein transplanting insulin-producing cells comprises transplanting approximately 3,000 to 5,000 islet equivalent cells per kilogram of patient body weight.Clause 8. The method of clause 1, further comprising initiating an immunosuppression regimen prior to transplanting the insulin-producing cells.Clause 9. The method of clause 8, wherein the immunosuppression regimen is initiated approximately 4 weeks prior to transplanting the insulin-producing cells.Clause 10. The method of clause 8, wherein the immunosuppression regimen comprises administering at least one of anti-thymocyte globulin or basiliximab or etanercept or mycophenolate mofetil or tacrolimus.Clause 11. The method of clause 1 , wherein the validated psychological assessment instrument Clause comprises a Diabetes Distress Score.Attorney Docket No.: 410694-504001WOClause 12. The method of clause 1 , wherein the validated psychological assessment instrument comprises a Hypoglycemia Fear Survey.Clause 13. The method of clause 1 , wherein the validated psychological assessment instrument comprises a Clarke Hypoglycemia Awareness Scale.Clause 14. The method of clause 1, further comprising measuring C-peptide levels in the patient to assess graft function of the transplanted insulin-producing cells, wherein a C-peptide level of at least 0.3 ng / mL indicates successful engraftment.Clause 15. The method of clause 1, further comprising measuring Hemoglobin A1c levels in the patient to assess glycemic control, wherein a target Hemoglobin A1c level is less than 7.0 percent.Clause 16. The method of clause 1 , wherein the patient achieves insulin independence following engraftment of the transplanted insulin-producing cells.Clause 17. The method of clause 1 , wherein the patient has type 1 diabetes mellitus with hypoglycemia unawareness.Clause 18. A method for treating diabetes and reducing diabetes-related distress in a patient, comprising:surgically implanting a cell pouch bio-hybrid organ in the patient, wherein the cell pouch bio-hybrid organ comprises an implantable macro-encapsulation device;permitting vascularized tissue chambers to form within the cell pouch bio-hybrid organ through integration with host tissue of the patient;transplanting a therapeutically effective amount of cells capable of producing insulin into the vascularized tissue chambers;enabling the transplanted cells to secrete insulin in response to blood glucose levels of the patient to achieve glycemic control; andevaluating a reduction in at least one of diabetes-related distress or fear of hypoglycemia or hypoglycemia unawareness using a validated assessment instrument. Clause 19. The method of clause 18, wherein the therapeutically effective amount of cells comprises approximately 3,000 to 5,000 islet equivalent cells per kilogram of patient body weight.Clause 20. The method of clause 18, wherein the validated assessment instrument comprises at least one of a Diabetes Distress Score ora Hypoglycemia FearSurvey-ll ora Clarke Hypoglycemia Awareness Scale.
[0075] Additional alternative embodiments of the technology described herein can be defined according to any of the following numbered illustrative clauses:Clause 1. A method for enhancing quality of life in a patient with diabetes, comprising:implanting a macro-encapsulation device in the patient;Attorney Docket No.: 410694-504001WOallowing the macro-encapsulation device to vascularize to form vascularized tissue chambers;transplanting insulin-producing cells into the vascularized tissue chambers to establish a functional cell graft;permitting the functional cell graft to sense blood glucose levels and secrete insulin in response thereto to achieve glycemic control; andassessing quality of life of the patient using at least one validated quality of life assessment instrument to determine a measurable reduction in diabetes-related psychological burden.Clause 2. The method of clause 1, wherein the macro-encapsulation device comprises a cell pouch bio-hybrid organ.Clause 3. The method of clause 1, wherein allowing the macro-encapsulation device to vascularize comprises a vascularization period of approximately 6 to 8 weeks.Clause 4. The method of clause 1, wherein the insulin-producing cells comprise purified human donor islets.Clause 5. The method of clause 1 , wherein the insulin-producing cells comprise stem cell-derived cells.Clause 6. The method of clause 1 , wherein the insulin-producing cells comprise xenogeneic cells. Clause 7. The method of clause 1, wherein transplanting the insulin-producing cells comprises transplanting approximately 3,000 to 5,000 islet equivalent cells per kilogram of patient body weight.Clause 8. The method of clause 1 , further comprising:initiating an immunosuppression regimen prior to transplanting the insulin-producing cells.Clause 9. The method of clause 8, wherein the immunosuppression regimen comprises administering at least one of anti-thymocyte globulin, basiliximab, etanercept, mycophenolate mofetil, or tacrolimus.Clause 10. The method of clause 8, wherein initiating the immunosuppression regimen occurs approximately 4 weeks before transplanting the insulin-producing cells.Clause 11. The method of clause 1 , wherein the at least one validated quality of life assessment instrument comprises a Diabetes Distress Score instrument configured to measure emotional burden associated with diabetes.Clause 12. The method of clause 1 , wherein the at least one validated quality of life assessment instrument comprises a Clarke Hypoglycemia Awareness Scale configured to assess awareness of hypoglycemia.Clause 13. The method of clause 1 , wherein the at least one validated quality of life assessment instrument comprises a Hypoglycemia Fear Survey configured to measure fear of hypoglycemia.Attorney Docket No.: 410694-504001WOClause 14. The method of clause 1, further comprising:measuring C-peptide levels in the patient to assess function of the functional cell graft, wherein a C-peptide level of at least approximately 0.3 ng / mL indicates successful engraftment.Clause 15. The method of clause 1, further comprising:measuring hemoglobin A1c levels in the patient, wherein a hemoglobin A1c level below approximately 7.0% indicates improved glycemic control.Clause 16. The method of clause 1 , wherein assessing quality of life comprises assessing the patient before implanting the macro-encapsulation device and at approximately 180 days after transplanting the insulin-producing cells.Clause 17. The method of clause 1 , wherein the measurable reduction in diabetes-related psychological burden comprises at least one of a reduction in diabetes-related distress, a reduction in fear of hypoglycemia, or an improvement in hypoglycemia awareness.Clause 18. The method of clause 1 , wherein the patient has type 1 diabetes mellitus with hypoglycemia unawareness.Clause 19. A system for treating diabetes and enhancing quality of life in a patient, comprising:a macro-encapsulation device configured to be implanted in the patient and to form vascularized tissue chambers upon integration with host tissue;insulin-producing cells configured to be transplanted into the vascularized tissue chambers, wherein the insulin-producing cells are configured to sense blood glucose levels and secrete insulin in response thereto; andat least one quality of life assessment instrument configured to measure diabetes- related psychological burden in the patient to determine a reduction in at least one of diabetes-related distress, fear of hypoglycemia, or hypoglycemia unawareness.Clause 20. The system of clause 19, wherein the macro-encapsulation device comprises a cell pouch bio-hybrid organ, and wherein the insulin-producing cells comprise at least one of purified human donor islets, stem cell-derived cells, or xenogeneic cells.
[0076] In further additional alternative embodiments of the technology described herein can be defined according to any of the following numbered illustrative clauses:Clause 1. Insulin-producing cells for use in a method of treating diabetes and reducing diabetes- related distress in a patient, wherein the method comprises:implanting a macro-encapsulation device in the patient;allowing the implanted device to vascularize to form vascularized tissue chambers within the device;transplanting the insulin-producing cells into the vascularized tissue chambers of the device; andAttorney Docket No.: 410694-504001WOallowing the transplanted insulin-producing cells to engraft and secrete insulin in response to blood glucose levels.Clause 2. The insulin-producing cells for use according to clause 1 , wherein the macroencapsulation device is a cell pouch bio-hybrid organ.Clause 3. The insulin-producing cells for use according to clause 1 or 2, wherein the method comprises a vascularization period of 6 to 8 weeks prior to transplanting the insulinproducing cells.Clause 4. The insulin-producing cells for use according to any one of clauses 1 to 3, wherein the insulin-producing cells are selected from the group consisting of purified human donor islets, stem cell-derived cells, and xenogeneic cells.Clause 5. The insulin-producing cells for use according to any one of clauses 1 to 4, wherein transplanting the insulin-producing cells comprises transplanting 3,000 to 5,000 islet equivalent cells per kilogram of patient body weight.Clause 6. The insulin-producing cells for use according to any one of clauses 1 to 5, wherein the method further comprises administering an immunosuppression regimen to the patient prior to transplanting the insulin-producing cells.Clause 7. The insulin-producing cells for use according to clause 6, wherein the immunosuppression regimen is initiated 4 weeks prior to transplanting the insulin-producing cells, and / or wherein the immunosuppression regimen comprises administering at least one of anti-thymocyte globulin, basiliximab, etanercept, mycophenolate mofetil, or tacrolimus. Clause 8. The insulin-producing cells for use according to any one of clauses 1 to 7, wherein the reduction in diabetes-related distress is measurable by a validated psychological assessment instrument selected from the group consisting of a Diabetes Distress Score, a Hypoglycemia Fear Survey, and a Clarke Hypoglycemia Awareness Scale.Clause 9. The insulin-producing cells for use according to any one of clauses 1 to 8, wherein the method further comprises measuring C-peptide levels in the patient to assess graft function, wherein a C-peptide level of at least 0.3 ng / mL indicates successful engraftment.Clause 10. The insulin-producing cells for use according to any one of clauses 1 to 9, wherein the method further comprises measuring Hemoglobin A1c levels in the patient to assess glycemic control, wherein a target Hemoglobin A1c level is less than 7.0 percent.Clause 11. The insulin-producing cells for use according to any one of clauses 1 to 10, wherein the patient achieves insulin independence following engraftment of the transplanted insulinproducing cells.Clause 12. The insulin-producing cells for use according to any one of clauses 1 to 11 , wherein the patient has type 1 diabetes mellitus with hypoglycemia unawareness.Clause 13. A system for use in a method of treating diabetes and reducing diabetes-related distress in a patient, the system comprising:Attorney Docket No.: 410694-504001WOa macro-encapsulation device configured for surgical implantation and vascularization within the patient to form vascularized tissue chambers; andinsulin-producing cells for transplantation into the vascularized tissue chambers; wherein the method comprises implanting the macro-encapsulation device, allowing the device to vascularize, and transplanting the insulin-producing cells into the vascularized tissue chambers to engraft and secrete insulin in response to blood glucose levels.Clause 14. The system for use according to clause 13, wherein the macro-encapsulation device is a cell pouch bio-hybrid organ, and wherein the insulin-producing cells are selected from the group consisting of purified human donor islets, stem cell-derived cells, and xenogeneic cells.Clause 15. The system for use according to clause 13 or 14, wherein the reduction in diabetes- related distress comprises a reduction in fear of hypoglycemia or hypoglycemia unawareness, measurable by a validated assessment instrument selected from the group consisting of a Diabetes Distress Score, a Hypoglycemia FearSurvey-ll, and a Clarke Hypoglycemia Awareness Scale.
[0077] The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize. For example, while method steps or functions are presented in a given order, alternative embodiments may perform functions in a different order, or functions may be performed substantially concurrently. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the disclosure can be modified, if necessary, to employ the compositions, functions and concepts of the above references and application to provide yet further embodiments of the disclosure. Moreover, due to biological functional equivalency considerations, some changes can be made in protein structure without affecting the biological or chemical action in kind or amount. These and other changes can be made to the disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.
[0078] Specific elements of any of the foregoing embodiments can be combined or substituted for elements in other embodiments. Furthermore, while advantages associated with certain embodiments of the disclosure have been described in the context of theseAttorney Docket No.: 410694-504001WDembodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure.
[0079] The technology described herein is further illustrated by the following examples which in no way should be construed as being further limiting. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below.EXAMPLES
[0080] The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention and are not intended to limit the invention.EXAMPLE 1 QUALITY OF LIFE ASSESSMENT IN DIABETIC PATIENTS T RANSPLANTED WITH ISLET CELLS IN CELL POUCH BIO-HYBRID ORGANS
[0081] The purpose of the current study was to conduct a quality of life assessment in diabetic patients transplanted with islet cells in Cell Pouch bio-hybrid organs. The study was a Phase l / l I, non-randomized, open label, single-arm, company-sponsored trial. Subjects with hypoglycemia unawareness enrolled in the study under informed consent were implanted with the Cell Pouch. Following vascularized tissue development in the Cell Pouch, an initial dose of purified islets under strict release criteria were transplanted into the Cell Pouch.FUNCTIONALITY OF THE CELL POUCH BIO-HYBRID ORGAN
[0082] The cell pouch bio-hybrid organ used in the clinical trial is described in International Patent Application WO 2011 / 02597721and International Patent Application WO 2020 / 223670.22Data described below relates to the cell pouch bio-hybrid organ with human donor islets - prior to portal vein top up. The Cell Pouch is an implantable macroencapsulation device for the long-term survival and function of therapeutic cells (donor, stem cell derived cells and xenogeneic cells) which then release proteins and / or hormones as required to treat disease. The device is designed to eliminate concerns of fibrosis upon implantation by incorporating with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells.
[0083] BETA and BETA-2 scores were used to assess engraftment and function of islets after transplantation into the Cell Pouch. Both tests are industry standard composite scores derived from a single fasting blood sample, incorporating factors such as C-peptide (BETA-2:Attorney Docket No.: 410694-504001WQfasting; BETA: stimulated), fasting plasma glucose, HbA1c, and average daily insulin usage. Analysis of these data showed evidence of successful islet engraftment into the cell pouch and C-peptide production, indicating integration of the transplanted Islet cells in the vascularized cell pouch and restoration of endogenous insulin secretion in study participants.
[0084] All 12 study participants had their fasting and stimulated C-peptide levels measured. C-peptide is a byproduct created when the implanted islets produce insulin. For successful islet transplantation, a minimum C-peptide level of 0.3 ng / mL (0.1 nmol / L) is generally considered a threshold for graft function. Stimulated C-peptide levels (after a mixed meal tolerance test) are often used, with values above 0.2 ng / mL (0.07 nmol / L) indicating good graft function. Nine patients showed C-peptide levels greater than or equal to 0.3 nanograms per milliliter (ng / mL), indicating insulin production by the cell pouch bio-hybrid organ and islet cell engraftment.Results
[0085] Interim data from 12 patients with transplanted human donor islet cells in Cohort A and ongoing Cohort B show patients achieved insulin independence, islet cell engraftment in Cell Pouch, islet function, islet survival, improved glycemic control, improved patient reported quality of life (QOL) and improved awareness of hypoglycemia and increased sensitivity to severe hypoglycemic symptoms. Improvement in patient outcomes was correlated with a cumulative increase in the quantity of transplanted islets.
[0086] C-peptide is a biomarker that measures the amount of insulin produced by the transplanted islets. For successful islet transplantation, a C-peptide level of 0.3 ng / mL (0.1 nmol / L) is generally considered a threshold for graft function. Seven of 12 patients showed C-peptide levels of 0.3 ng / mL or greater, indicating successful islet cell engraftment and insulin production by islets transplanted to the Cell Pouch alone. The interim data as analyzed using industry standard composite BETA and BETA-2 scores, as well as histology of explanted Cell Pouches provided further evidence of engraftment and function of islet cells after transplantation into the Cell Pouch alone.
[0087] FIG. 2 summarizes BETA-2 and BETA scores for study participants following transplantation of human donor islet cells into vascularized Cell Pouch bio-hybrid organs. The top panel of FIG. 2 shows BETA-2 scores, which are derived from fasting metabolic variables and provide an estimate of islet graft function following islet transplantation. In the order shown in FIG. 2, the BETA-2 scores were 3.07, 2.35, 0, 0, 0, 0, 1.43, 2.02, 2.25, 1.95, 0.92, and 0.70. Thus, a majority of the study participants exhibited non-zero BETA-2 scores following transplantation. The lower panel of FIG. 2 shows BETA scores, which are composite scoresAttorney Docket No.: 410694-504001WObased on parameters including fasting plasma glucose, HbA1c, insulin independence or use of insulin and / or oral hypoglycemic agents, and stimulated C-peptide levels. In the order shown in FIG. 2, the BETA scores were 5, 1, 5, 4, 0, 4, 3, 3, 4, 4, 3, and 4. These BETA-2 and BETA score data provide evidence of engraftment and function of the transplanted islet cells within the vascularized Cell Pouch bio-hybrid organs, including restoration of endogenous insulin secretion in at least a subset of the study participants.
[0088] Measured HbA1c (a blood test that shows the average blood sugar levels over the past 2-3 months) in patients with Cell Pouch alone, showed that 9 of 12 patients had a reduced value within the American Diabetes Association (ADA) recommended range of <7.0%. Of the remaining three patients, one experienced a 24% reduction in HbA1c from 10.3% to 7.8% and the other two maintained a normal HbA1c value of <7% as measured at baseline. Published clinical studies found that each 1% reduction in A1c was associated with a 14 % reduced risk of myocardial infarction. A single portal vein transplant resulted in all Patients having a recommended HbA1c of <7.0% that was maintained for the duration of the study.
[0089] FIG. 3 summarizes longitudinal HbA1c data for the twelve study participants. HbA1c, or Hemoglobin A1c, provides a measure of average blood glucose levels over approximately the preceding two to three months and is a clinically relevant marker of glycemic control. In FIG. 3, HbA1c values are plotted as a percentage over sequential study measurements for participants 1101-003, 1101-007, 1101-008, 1101-009, 1101-010, 1101-011, 1101-015, 1101-016, 1101-019, 1101-020, 1101-021, and 1101-023. The shaded region in the graph identifies the recommended HbA1c range for patients with type 1 diabetes, including HbA1c values below 7.0%.
[0090] As shown in FIG. 3, all twelve study participants achieved an HbA1c value below 7.0% during the course of the study. Certain participants exhibited elevated HbA1c values during earlier study measurements, including participant 1101-007, who had plotted HbA1c values of 10.3%, and participant 1101-010, who had a plotted HbA1c value of 8.4%. Over the course of the study, HbA1c values for the participants converged toward the recommended range. In the order of participants listed in the legend of FIG. 3, the final plotted HbA1c values were 5.2%, 6.5%, 5.6%, 5.9%, 6.7%, 5.3%, 5.5%, 6.6%, 5.0%, 5.6%, 5.7%, and 5.4%, respectively. These data provide objective evidence of improved glycemic control in the study participants and support the quality-of-life improvements described herein, including reductions in diabetes-related distress and fear of hypoglycemia associated with the Cell Pouch bio-hybrid organ treatment protocol.Attorney Docket No.: 410694-504001WO
[0091] These interim data showed successful functionality of the Cell Pouch Bio-hybrid Organ. These data are positive and indicate that a threshold cumulative quantity of implanted islets can be reached to show clinical effect.QUALITY OF LIFE ASSESSMENT
[0092] For people with T 1 D, the experience of hypoglycemia haunts them 24 hours a day; it is terrifying, it is debilitating. The objective of the present study was to assess if the Cell Pouch Bio-hybrid Organ improved the quality of life of patients in addition to providing them with insulin independence. Patients self-reported data on one industry standard survey that assesses hypoglycemia awareness and two industry standard Quality of Life surveys.Results
[0093] Clarke Hypoglycemia Index: The Clarke Hypoglycemia Index was used to assess hypoglycemia awareness in the study participants. The Clarke Hypoglycemia Index is a questionnaire that evaluates whether a patient experiences symptoms of hypoglycemia, or low blood sugar, and whether the patient recognizes when hypoglycemia is occurring. A higher Clarke Hypoglycemia Index score generally corresponds to a higher likelihood of impaired awareness of hypoglycemia.
[0094] FIG. 4 summarizes paired Clarke Hypoglycemia Index scores for the twelve study participants at initial screening and at 180 days after treatment. In FIG. 4, each participant is represented by a pair of bars, with the first bar corresponding to the initial screening measurement and the adjacent second bar corresponding to the day-180 posttreatment measurement. Thus, 11 of the 12 study participants exhibited a lower Clarke Hypoglycemia Index score at day 180, while one participant maintained the same score. These data support an improvement in hypoglycemia awareness and increased sensitivity to severe hypoglycemic symptoms following treatment with the Cell Pouch bio-hybrid organ protocol.
[0095] Hypoglycemia Fear Survey-ll (HFS-II) The HFS-II is a validated measure of fear of hypoglycemia in people living with diabetes. Lower scores reflect a decrease in worry and avoidance behaviors related to hypoglycemia, which have positive implications for diabetes management, including better adherence to treatment plans, improved glucose control and a reduction in avoidance behaviors that can negatively impact blood sugar levels. In the present study, 10 of 12 patients reported a reduction in HFS-II scale indicating a reduction in fear of hypoglycemia.
[0096] FIG. 5 summarizes Hypoglycemia Fear Survey-ll (HFS-II) total scores for the twelve study participants at patient screening and at 180 days after the second treatment orAttorney Docket No.: 410694-504001WQtransplantation time point, identified in the figure as “Post Tx #2.” The HFS-II includes a Worry scale and a Behavior scale, and individual items are scored on a 5-point scale from 0 to 4, with 0 corresponding to “never” and 4 corresponding to “almost always.” The total score is obtained by summing individual item scores across the Worry and Behavior scales. Higher total scores indicate a greater fear of hypoglycemia.
[0097] In FIG. 5, each study participant is represented by a pair of bars. In the order of participants 1 through 12 shown in FIG. 5, the plotted patient-screening / day-180 post-Tx#2 total HFS-II score pairs are 106 / 53, 138 / 118, 81 / 86, 91 / 114, 88 / 83, 62 / 84, 111 / 104, 113 / 104, 126 / 84, 96 / 67, 96 / 68, and 86 / 53, respectively. As plotted, the mean total HFS-II score decreased from 99.5 at patient screening to 84.8 at 180 days post-Tx #2. Nine of the twelve study participants exhibited a lower total HFS-II score at the day-180 post-Tx #2 assessment than at patient screening. These data show that treatment with islet cells transplanted into vascularized Cell Pouch bio-hybrid organs was associated with a reduction in fear of hypoglycemia in a majority of the study participants.
[0098] Diabetes Distress Score (DDS): The DDS, a validated questionnaire designed to assess the emotional burden and distress associated with managing diabetes, was used to identify specific areas of concern. This includes emotional burden and regimen-related challenges to understand the psychological impact of living with T1D and any changes from baseline. Reduced diabetes distress can be associated with improved glycemic control, better self-care practices, and enhanced overall quality of life. In the present study, 10 of 12 patients had a lowering of their DDS, indicating a reduction in distress associated with managing their T1D.
[0099] FIG. 6 summarizes DDS total scores for the twelve study participants at patient screening and at 180 days after the second treatment or transplantation time point, identified in the figure as “Post Tx #2.” In the illustrated assessment, participants rated the extent to which they experienced diabetes-related distress on a six-point scale, where 1 indicates “not a problem” and 6 indicates a “serious problem.” Higher DDS scores indicate greater diabetes-related distress.
[0100] In FIG. 6, each study participant is represented by a pair of bars, with the first bar corresponding to patient screening and the adjacent second bar corresponding to 180 days post-Tx #2. In the order of participants 1 through 12 shown in FIG. 6, the plotted patient-screening / day-180 post-Tx #2 DDS total score pairs are 3.0 / 1.9, 5.2 / 3.4, 1.2 / 2.0, 3.0 / 1.9, 3.1 / 1.9, 2.4 / 2.1, 2.9 / 2.6, 3.2 / 2.9, 2.8Z2.7, 1.4 / 1.4, 3.4Z2.5, and 2.8 / 1.6, respectively. As plotted, the mean DDS total score decreased from 2.87 at patient screening to 2.24 at 180 days post-TxAttorney Docket No.: 410694-504001WQ#2. Ten of the twelve study participants exhibited a lower DDS total score at the day-180 post-Tx #2 assessment than at patient screening, one participant had an unchanged score, and one participant had an increased score. These data support that treatment with islet cells transplanted into vascularized Cell Pouch bio-hybrid organs was associated with reduced diabetes-related distress in a majority of the study participants.
[0101] These interim data showed improved quality of life in patients with an implanted Cell Pouch Bio-hybrid Organ. This improvement may help prevent the long-term comorbidities associated with diabetes.CONCLUSION
[0102] Data from the ongoing Phase 1 / 2 Clinical Trial demonstrated islet engraftment in the cell pouch, islet functionality, and C-peptide production. Data showed improved sensitivity to hypoglycemia, a reduction of fear of hypoglycemic events, and a reduction in distress associated with managing type 1 diabetes (T1D). CGM data showed an improvement in glycemic control with increased time in range and reduction in hypoglycemia.
[0103] These data demonstrate that the transplanted cell pouch bio-hybrid organ is working. These data also demonstrate that the transplanted cell pouch bio-hybrid organ not only helps to manage the physiological aspects of T1 D but also helps to manage the detrimental psychological and anxiety aspects of T1 D.REFERENCES:1Ducat, L., etal. (2014). “The mental health comorbidities of diabetes." JAMA, 312(7): 691-692.2Formanek, T., et al. (2024). “Childhood-onset type 1 diabetes and subsequent adult psychiatric disorders: a nationwide cohort and genome-wide Mendelian randomization study.” Nat. Mental Health, 2: 1062-1070.3van Duinkerken, E., et al. (2020). “The cognitive and psychological effects of living with type 1 diabetes:a narrative review." Diabetic Medicine, 37(4): 555-563.4Clarke, W.L., et al. (1995). “Reduced Awareness of Hypoglycemia in Adults With IDDM: A prospective study of hypoglycemic frequency and associated symptoms." Care, 18(4): 517-522.5Ryan, E.A., et al. (2004). “Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation." Diabetes, 53(4): 955-962.6Papas, K.K., et al. (2009). “Islet Assessment for Transplantation ." Curr. Opin. Organ Transplant., 14(6):674-682.7Colton, C.K., etal. (2007). “Characterizations of islet preparations." Cellular Transplantation: From Laboratory to Clinic. 85-134.8Papas, K.K., et al. (2009). “Islet Assessment for Transplantation." Curr. Opin. Organ Transplant., 14(6):674-682.Attorney Docket No.: 410694-504001WO9THE MERCK MANUAL OF DIAGNOSIS AND THE APY, (2011). 19thEdition, published by Merck Sharp & Dohme Corp., (ISBN 978-0-911910-19-3).10T HE ENCYCLOPEDIA OF MOLECULAR CELL BIOLOGY AND MOLECULAR MEDICINE, Robert S. Porter et al.(eds.), published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908).11MOLECULAR BIOLOGY AND BIOTECHNOLOGY: A COMPREHENSIVE DESK REFERENCE, (1995). Robert A.Meyers (ed.), published by VCH Publishers, Inc. (ISBN 1-56081-569-8).12IMMUNOLOGY, (2006). Werner Luttmann, published by Elsevier.13JANEWAY'S IMMUNOBIOLOGY, (2014). Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), Taylor & Francis Limited, (ISBN 0815345305, 9780815345305).14LEWIN'S GENES XI, (2014). published by Jones & Bartlett Publishers (ISBN-1449659055).15Michael Richard Green and Joseph Sambrook, (2012). MOLECULAR CLONING: A LABORATORY MANUAL, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (ISBN 1936113414).16Davis et al., (2012). BASIC METHODS IN MOLECULAR BIOLOGY, Elsevier Science Publishing, Inc., New York, USA (ISBN 044460149X).17LABORATORY METHODS IN ENZYMOLOGY: DNA, (2013). Jon Lorsch (ed.) Elsevier (ISBN 0124199542).18CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (CPMB), (2014). Frederick M. Ausubel (ed.), John Wiley and Sons (ISBN 047150338X, 9780471503385).19CURRENT PROTOCOLS IN PROTEIN SCIENCE (CPPS), (2005). John E. Coligan (ed.), John Wiley and Sons, Inc.20CURRENT PROTOCOLS IN IMMUNOLOGY (CPI) (2003). John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc. (ISBN 0471142735, 9780471142737).21Hasilo, C., et al. (2011). “Methods and Devices for Cellular Transplantation." International Patent Application WO 2011 / 025977.22Toleikis, P.M., et al. (2020). “Methods of Treating Diabetes Using Devices for Cellular Transplantation." International Patent Application WO 2020 / 223670.
[0104] All patents and other publications; including literature references, issued patents, published patent applications, and co-pending patent applications; cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the technology described herein. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.Attorney Docket No.: 410694-504001WQ
[0105] The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the present aspects and embodiments. The present aspects and embodiments are not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect and other functionally equivalent embodiments are within the scope of the disclosure. Various modifications in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects described herein are not necessarily encompassed by each embodiment. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.
Claims
Attorney Docket No.: 410694-504001WQCLAIMS WHAT IS CLAIMED IS:
1. A method for enhancing quality of life in a patient with diabetes, comprising: implanting a macro-encapsulation device in the patient;allowing the implanted device to vascularize to form vascularized tissue chambers within the device;transplanting insulin-producing cells into the vascularized tissue chambers of the device; allowing the transplanted insulin-producing cells to engraft within the vascularized tissue chambers;permitting the engrafted insulin-producing cells to sense blood glucose levels and secrete insulin in response thereto, thereby providing stable glycemic control; and assessing quality of life of the patient using a validated psychological assessment instrument to determine a measurable reduction in diabetes-related distress.
2. The method of claim 1, wherein the macro-encapsulation device comprises a cell pouch bio-hybrid organ.
3. The method of claim 1, wherein allowing the implanted device to vascularize comprises a vascularization period of approximately 6 to 8 weeks.
4. The method of claim 1, wherein the insulin-producing cells comprise purified human donor islets.
5. The method of claim 1, wherein the insulin-producing cells comprise stem cell-derived cells.
6. The method of claim 1, wherein the insulin-producing cells comprise xenogeneic cells.
7. The method of claim 1, wherein transplanting insulin-producing cells comprises transplanting approximately 3,000 to 5,000 islet equivalent cells per kilogram of patient body weight.
8. The method of claim 1, further comprising initiating an immunosuppression regimen prior to transplanting the insulin-producing cells.
9. The method of claim 8, wherein the immunosuppression regimen is initiated approximately 4 weeks prior to transplanting the insulin-producing cells.Attorney Docket No.: 410694-504001WO10. The method of claim 8, wherein the immunosuppression regimen comprises administering at least one of anti -thymocyte globulin or basiliximab or etanercept or mycophenolate mofetil or tacrolimus.
11. The method of claim 1 , wherein the validated psychological assessment instrument comprises a Diabetes Distress Score.
12. The method of claim 1, wherein the validated psychological assessment instrument comprises a Hypoglycemia Fear Survey.
13. The method of claim 1, wherein the validated psychological assessment instrument comprises a Clarke Hypoglycemia Awareness Scale.
14. The method of claim 1 , further comprising measuring C-peptide levels in the patient to assess graft function of the transplanted insulin-producing cells, wherein a C-peptide level of at least 0.3 ng / mL indicates successful engraftment.
15. The method of claim 1 , further comprising measuring Hemoglobin A1 c levels in the patient to assess glycemic control, wherein a target Hemoglobin A1c level is less than 7.0 percent.
16. The method of claim 1, wherein the patient achieves insulin independence following engraftment of the transplanted insulin-producing cells.
17. The method of claim 1, wherein the patient has type 1 diabetes mellitus with hypoglycemia unawareness.
18. A method for treating diabetes and reducing diabetes-related distress in a patient, comprising:surgically implanting a cell pouch bio-hybrid organ in the patient, wherein the cell pouch bio-hybrid organ comprises an implantable macro-encapsulation device;permitting vascularized tissue chambers to form within the cell pouch bio-hybrid organ through integration with host tissue of the patient;transplanting a therapeutically effective number of cells capable of producing insulin into the vascularized tissue chambers;enabling the transplanted cells to secrete insulin in response to blood glucose levels of the patient to achieve glycemic control; andevaluating a reduction in at least one of diabetes-related distress or fear of hypoglycemia or hypoglycemia unawareness using a validated assessment instrument.Attorney Docket No.: 410694-504001WO19. The method of claim 18, wherein the therapeutically effective amount of cells comprises approximately 3,000 to 5,000 islet equivalent cells per kilogram of patient body weight.
20. The method of claim 18, wherein the validated assessment instrument comprises at least one of a Diabetes Distress Score or a Hypoglycemia Fear Survey-ll or a Clarke Hypoglycemia Awareness Scale.
21. Insulin-producing cells for use in a method of treating diabetes and reducing diabetes-related distress in a patient, wherein the method comprises:implanting a macro-encapsulation device in the patient;allowing the implanted device to vascularize to form vascularized tissue chambers within the device;transplanting the insulin-producing cells into the vascularized tissue chambers of the device; andallowing the transplanted insulin-producing cells to engraft and secrete insulin in response to blood glucose levels, andwherein the reduction in diabetes-related distress is measurable by a validated psychological assessment instrument selected from the group consisting of a Diabetes Distress Score, a Hypoglycemia Fear Survey, and a Clarke Hypoglycemia Awareness Scale.
22. The insulin-producing cells for use according to claim 21, wherein the macroencapsulation device is a cell pouch bio-hybrid organ.
23. The insulin-producing cells for use according to claim 21 or 22, wherein the method comprises a vascularization period of 6 to 8 weeks prior to transplanting the insulin-producing cells.
24. The insulin-producing cells for use according to any one of claims 21 to 23, wherein the insulin-producing cells are selected from the group consisting of purified human donor islets, stem cell-derived cells, and xenogeneic cells.
25. The insulin-producing cells for use according to any one of claims 21 to 24, wherein transplanting the insulin-producing cells comprises transplanting 3,000 to 5,000 islet equivalent cells per kilogram of patient body weight.
26. The insulin-producing cells for use according to any one of claims 21 to 25, wherein the method further comprises administering an immunosuppression regimen to the patient prior to transplanting the insulin-producing cells.Attorney Docket No.: 410694-504001WQ27. The insulin-producing cells for use according to claim 26, wherein the immunosuppression regimen is initiated 4 weeks prior to transplanting the insulin-producing cells, and / or wherein the immunosuppression regimen comprises administering at least one of anti-thymocyte globulin, basiliximab, etanercept, mycophenolate mofetil, or tacrolimus.
28. The insulin-producing cells for use according to any one of claims 21 to 27, wherein the method further comprises measuring C-peptide levels in the patient to assess graft function, wherein a C-peptide level of at least 0.3 ng / mL indicates successful engraftment.
29. The insulin-producing cells for use according to any one of claims 21 to 28, wherein the method further comprises measuring Hemoglobin A1c levels in the patient to assess glycemic control, wherein a target Hemoglobin A1c level is less than 7.0 percent.
30. The insulin-producing cells for use according to any one of claims 21 to 29, wherein the patient achieves insulin independence following engraftment of the transplanted insulinproducing cells.
31. The insulin-producing cells for use according to any one of claims 21 to 30, wherein the patient has type 1 diabetes mellitus with hypoglycemia unawareness.
32. A system for use in a method of treating diabetes and reducing diabetes-related distress in a patient, the system comprising:a macro-encapsulation device configured for surgical implantation and vascularization within the patient to form vascularized tissue chambers; andinsulin-producing cells for transplantation into the vascularized tissue chambers; wherein the method comprises implanting the macro-encapsulation device, allowing the device to vascularize, and transplanting the insulin-producing cells into the vascularized tissue chambers to engraft and secrete insulin in response to blood glucose levels, andwherein the reduction in diabetes-related distress comprises a reduction in fear of hypoglycemia or hypoglycemia unawareness, measurable by a validated assessment instrument selected from the group consisting of a Diabetes Distress Score, a Hypoglycemia Fear Survey-ll, and a Clarke Hypoglycemia Awareness Scale.
33. The system for use according to claim 32, wherein the macro-encapsulation device is a cell pouch bio-hybrid organ, and wherein the insulin-producing cells are selected from the group consisting of purified human donor islets, stem cell-derived cells, and xenogeneic cells.
